IBDEI02P ; ; 13-FEB-2014
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 13, 2014
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,3096,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3096,1,1,0)
 ;;=1^285.0
 ;;^UTILITY(U,$J,358.3,3096,1,8,0)
 ;;=8^Sideroblastic Anemia
 ;;^UTILITY(U,$J,358.3,3096,2)
 ;;=^7204
 ;;^UTILITY(U,$J,358.3,3097,0)
 ;;=285.3^^29^255^9
 ;;^UTILITY(U,$J,358.3,3097,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3097,1,1,0)
 ;;=1^285.3
 ;;^UTILITY(U,$J,358.3,3097,1,8,0)
 ;;=8^Antineoplastic Chemo Ind Anemia
 ;;^UTILITY(U,$J,358.3,3097,2)
 ;;=^338232
 ;;^UTILITY(U,$J,358.3,3098,0)
 ;;=285.8^^29^255^39
 ;;^UTILITY(U,$J,358.3,3098,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3098,1,1,0)
 ;;=1^285.8
 ;;^UTILITY(U,$J,358.3,3098,1,8,0)
 ;;=8^Oth Spec Anemia
 ;;^UTILITY(U,$J,358.3,3098,2)
 ;;=^87876
 ;;^UTILITY(U,$J,358.3,3099,0)
 ;;=283.2^^29^255^21
 ;;^UTILITY(U,$J,358.3,3099,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3099,1,1,0)
 ;;=1^283.2
 ;;^UTILITY(U,$J,358.3,3099,1,8,0)
 ;;=8^Hemolytic d/t Hemolysis
 ;;^UTILITY(U,$J,358.3,3099,2)
 ;;=^55770
 ;;^UTILITY(U,$J,358.3,3100,0)
 ;;=280.0^^29^255^27
 ;;^UTILITY(U,$J,358.3,3100,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3100,1,1,0)
 ;;=1^280.0
 ;;^UTILITY(U,$J,358.3,3100,1,8,0)
 ;;=8^Iron Def Anemia,d/t Blood Loss Anemia
 ;;^UTILITY(U,$J,358.3,3100,2)
 ;;=^267971
 ;;^UTILITY(U,$J,358.3,3101,0)
 ;;=280.1^^29^255^28
 ;;^UTILITY(U,$J,358.3,3101,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3101,1,1,0)
 ;;=1^280.1
 ;;^UTILITY(U,$J,358.3,3101,1,8,0)
 ;;=8^Iron Def Anemia,d/t Dietary Intake
 ;;^UTILITY(U,$J,358.3,3101,2)
 ;;=^267972
 ;;^UTILITY(U,$J,358.3,3102,0)
 ;;=280.8^^29^255^26
 ;;^UTILITY(U,$J,358.3,3102,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3102,1,1,0)
 ;;=1^280.8
 ;;^UTILITY(U,$J,358.3,3102,1,8,0)
 ;;=8^Iron Def Anemia,Oth Spec
 ;;^UTILITY(U,$J,358.3,3102,2)
 ;;=^88088
 ;;^UTILITY(U,$J,358.3,3103,0)
 ;;=284.09^^29^255^13
 ;;^UTILITY(U,$J,358.3,3103,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3103,1,1,0)
 ;;=1^284.09
 ;;^UTILITY(U,$J,358.3,3103,1,8,0)
 ;;=8^Constitutional Aplastic Anemia,Oth
 ;;^UTILITY(U,$J,358.3,3103,2)
 ;;=^334036
 ;;^UTILITY(U,$J,358.3,3104,0)
 ;;=286.9^^29^256^9
 ;;^UTILITY(U,$J,358.3,3104,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3104,1,1,0)
 ;;=1^286.9
 ;;^UTILITY(U,$J,358.3,3104,1,8,0)
 ;;=8^Defective Coagulation,Unspec
 ;;^UTILITY(U,$J,358.3,3104,2)
 ;;=^87267
 ;;^UTILITY(U,$J,358.3,3105,0)
 ;;=446.6^^29^256^26
 ;;^UTILITY(U,$J,358.3,3105,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3105,1,1,0)
 ;;=1^446.6
 ;;^UTILITY(U,$J,358.3,3105,1,8,0)
 ;;=8^Thrombotic Microangiopathy
 ;;^UTILITY(U,$J,358.3,3105,2)
 ;;=^119061
 ;;^UTILITY(U,$J,358.3,3106,0)
 ;;=451.9^^29^256^25
 ;;^UTILITY(U,$J,358.3,3106,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3106,1,1,0)
 ;;=1^451.9
 ;;^UTILITY(U,$J,358.3,3106,1,8,0)
 ;;=8^Thrombophlebitis
 ;;^UTILITY(U,$J,358.3,3106,2)
 ;;=^93357
 ;;^UTILITY(U,$J,358.3,3107,0)
 ;;=287.5^^29^256^23
 ;;^UTILITY(U,$J,358.3,3107,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3107,1,1,0)
 ;;=1^287.5
 ;;^UTILITY(U,$J,358.3,3107,1,8,0)
 ;;=8^Thrombocytopenia Nos
 ;;^UTILITY(U,$J,358.3,3107,2)
 ;;=^118988
 ;;^UTILITY(U,$J,358.3,3108,0)
 ;;=287.30^^29^256^21
 ;;^UTILITY(U,$J,358.3,3108,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3108,1,1,0)
 ;;=1^287.30
 ;;^UTILITY(U,$J,358.3,3108,1,8,0)
 ;;=8^Primary Thrombocytopenia (ITP)
 ;;^UTILITY(U,$J,358.3,3108,2)
 ;;=^332841
 ;;^UTILITY(U,$J,358.3,3109,0)
 ;;=238.71^^29^256^24
 ;;^UTILITY(U,$J,358.3,3109,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3109,1,1,0)
 ;;=1^238.71
 ;;^UTILITY(U,$J,358.3,3109,1,8,0)
 ;;=8^Thrombocytosis,Essential
 ;;^UTILITY(U,$J,358.3,3109,2)
 ;;=^334027
 ;;^UTILITY(U,$J,358.3,3110,0)
 ;;=286.53^^29^256^4
 ;;^UTILITY(U,$J,358.3,3110,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3110,1,1,0)
 ;;=1^286.53
 ;;^UTILITY(U,$J,358.3,3110,1,8,0)
 ;;=8^Antiphospholipid w/ Hemor d/o
 ;;^UTILITY(U,$J,358.3,3110,2)
 ;;=^340503
 ;;^UTILITY(U,$J,358.3,3111,0)
 ;;=286.0^^29^256^7
 ;;^UTILITY(U,$J,358.3,3111,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3111,1,1,0)
 ;;=1^286.0
 ;;^UTILITY(U,$J,358.3,3111,1,8,0)
 ;;=8^Congenital Factor VII Disorder
 ;;^UTILITY(U,$J,358.3,3111,2)
 ;;=^27454
 ;;^UTILITY(U,$J,358.3,3112,0)
 ;;=286.1^^29^256^5
 ;;^UTILITY(U,$J,358.3,3112,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3112,1,1,0)
 ;;=1^286.1
 ;;^UTILITY(U,$J,358.3,3112,1,8,0)
 ;;=8^Cogenital Factor IX Disorder
 ;;^UTILITY(U,$J,358.3,3112,2)
 ;;=^27452
 ;;^UTILITY(U,$J,358.3,3113,0)
 ;;=286.2^^29^256^8
 ;;^UTILITY(U,$J,358.3,3113,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3113,1,1,0)
 ;;=1^286.2
 ;;^UTILITY(U,$J,358.3,3113,1,8,0)
 ;;=8^Congenital Factor XI Deficiency
 ;;^UTILITY(U,$J,358.3,3113,2)
 ;;=^27456
 ;;^UTILITY(U,$J,358.3,3114,0)
 ;;=286.3^^29^256^6
 ;;^UTILITY(U,$J,358.3,3114,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3114,1,1,0)
 ;;=1^286.3
 ;;^UTILITY(U,$J,358.3,3114,1,8,0)
 ;;=8^Congenital Def of Oth Clotting
 ;;^UTILITY(U,$J,358.3,3114,2)
 ;;=^27437
 ;;^UTILITY(U,$J,358.3,3115,0)
 ;;=286.4^^29^256^28
 ;;^UTILITY(U,$J,358.3,3115,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3115,1,1,0)
 ;;=1^286.4
 ;;^UTILITY(U,$J,358.3,3115,1,8,0)
 ;;=8^Von Willebrand's Disease
 ;;^UTILITY(U,$J,358.3,3115,2)
 ;;=^127267
 ;;^UTILITY(U,$J,358.3,3116,0)
 ;;=286.52^^29^256^2
 ;;^UTILITY(U,$J,358.3,3116,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3116,1,1,0)
 ;;=1^286.52
 ;;^UTILITY(U,$J,358.3,3116,1,8,0)
 ;;=8^Acquired Hemophilia
 ;;^UTILITY(U,$J,358.3,3116,2)
 ;;=^340502
 ;;^UTILITY(U,$J,358.3,3117,0)
 ;;=286.59^^29^256^16
 ;;^UTILITY(U,$J,358.3,3117,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3117,1,1,0)
 ;;=1^286.59
 ;;^UTILITY(U,$J,358.3,3117,1,8,0)
 ;;=8^Oth Hemor d/o d/t Anticoagulant
 ;;^UTILITY(U,$J,358.3,3117,2)
 ;;=^340504
 ;;^UTILITY(U,$J,358.3,3118,0)
 ;;=286.6^^29^256^10
 ;;^UTILITY(U,$J,358.3,3118,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3118,1,1,0)
 ;;=1^286.6
 ;;^UTILITY(U,$J,358.3,3118,1,8,0)
 ;;=8^Defibrination Syndrome
 ;;^UTILITY(U,$J,358.3,3118,2)
 ;;=^35673
 ;;^UTILITY(U,$J,358.3,3119,0)
 ;;=286.7^^29^256^1
 ;;^UTILITY(U,$J,358.3,3119,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3119,1,1,0)
 ;;=1^286.7
 ;;^UTILITY(U,$J,358.3,3119,1,8,0)
 ;;=8^Acquired Coagulation Factor Def
 ;;^UTILITY(U,$J,358.3,3119,2)
 ;;=^2235
 ;;^UTILITY(U,$J,358.3,3120,0)
 ;;=287.0^^29^256^3
 ;;^UTILITY(U,$J,358.3,3120,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3120,1,1,0)
 ;;=1^287.0
 ;;^UTILITY(U,$J,358.3,3120,1,8,0)
 ;;=8^Allergic Purpura
 ;;^UTILITY(U,$J,358.3,3120,2)
 ;;=^101365
 ;;^UTILITY(U,$J,358.3,3121,0)
 ;;=287.1^^29^256^22
 ;;^UTILITY(U,$J,358.3,3121,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3121,1,1,0)
 ;;=1^287.1
 ;;^UTILITY(U,$J,358.3,3121,1,8,0)
 ;;=8^Qualitative Platelet Defects
 ;;^UTILITY(U,$J,358.3,3121,2)
 ;;=^101922
 ;;^UTILITY(U,$J,358.3,3122,0)
 ;;=287.2^^29^256^17
 ;;^UTILITY(U,$J,358.3,3122,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3122,1,1,0)
 ;;=1^287.2
 ;;^UTILITY(U,$J,358.3,3122,1,8,0)
 ;;=8^Oth Nonthrombocytopenic Purpuras
 ;;^UTILITY(U,$J,358.3,3122,2)
 ;;=^87741
 ;;^UTILITY(U,$J,358.3,3123,0)
 ;;=287.31^^29^256^13
 ;;^UTILITY(U,$J,358.3,3123,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3123,1,1,0)
 ;;=1^287.31
 ;;^UTILITY(U,$J,358.3,3123,1,8,0)
 ;;=8^Immune Thrombocytopenic Purpura
 ;;^UTILITY(U,$J,358.3,3123,2)
 ;;=^332746
 ;;^UTILITY(U,$J,358.3,3124,0)
 ;;=287.32^^29^256^11
 ;;^UTILITY(U,$J,358.3,3124,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3124,1,1,0)
 ;;=1^287.32
 ;;^UTILITY(U,$J,358.3,3124,1,8,0)
 ;;=8^Evan's Syndrome
 ;;^UTILITY(U,$J,358.3,3124,2)
 ;;=^332747
 ;;^UTILITY(U,$J,358.3,3125,0)
 ;;=287.41^^29^256^20
 ;;^UTILITY(U,$J,358.3,3125,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3125,1,1,0)
 ;;=1^287.41
 ;;^UTILITY(U,$J,358.3,3125,1,8,0)
 ;;=8^Posttransfusion Purpura
 ;;^UTILITY(U,$J,358.3,3125,2)
 ;;=^339609
 ;;^UTILITY(U,$J,358.3,3126,0)
 ;;=287.49^^29^256^18
 ;;^UTILITY(U,$J,358.3,3126,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3126,1,1,0)
 ;;=1^287.49
 ;;^UTILITY(U,$J,358.3,3126,1,8,0)
 ;;=8^Oth Secondary Thrombocytopenia
 ;;^UTILITY(U,$J,358.3,3126,2)
 ;;=^339610
 ;;^UTILITY(U,$J,358.3,3127,0)
 ;;=287.8^^29^256^19
 ;;^UTILITY(U,$J,358.3,3127,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3127,1,1,0)
 ;;=1^287.8
 ;;^UTILITY(U,$J,358.3,3127,1,8,0)
 ;;=8^Oth Spec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,3127,2)
 ;;=^88074
 ;;^UTILITY(U,$J,358.3,3128,0)
 ;;=287.9^^29^256^27
 ;;^UTILITY(U,$J,358.3,3128,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3128,1,1,0)
 ;;=1^287.9
 ;;^UTILITY(U,$J,358.3,3128,1,8,0)
 ;;=8^Unspec Hemorrhagic Conditions
 ;;^UTILITY(U,$J,358.3,3128,2)
 ;;=^123920
 ;;^UTILITY(U,$J,358.3,3129,0)
 ;;=238.72^^29^256^14
 ;;^UTILITY(U,$J,358.3,3129,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3129,1,1,0)
 ;;=1^238.72
 ;;^UTILITY(U,$J,358.3,3129,1,8,0)
 ;;=8^Low Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,3129,2)
 ;;=^334028
 ;;^UTILITY(U,$J,358.3,3130,0)
 ;;=238.73^^29^256^12
 ;;^UTILITY(U,$J,358.3,3130,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3130,1,1,0)
 ;;=1^238.73
 ;;^UTILITY(U,$J,358.3,3130,1,8,0)
 ;;=8^Hi Grde Myelodysplastic Synd Lesions
 ;;^UTILITY(U,$J,358.3,3130,2)
 ;;=^334029
 ;;^UTILITY(U,$J,358.3,3131,0)
 ;;=238.75^^29^256^15
 ;;^UTILITY(U,$J,358.3,3131,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3131,1,1,0)
 ;;=1^238.75
 ;;^UTILITY(U,$J,358.3,3131,1,8,0)
 ;;=8^Myelodysplastic Syndrome,Unspec
 ;;^UTILITY(U,$J,358.3,3131,2)
 ;;=^334031
 ;;^UTILITY(U,$J,358.3,3132,0)
 ;;=205.00^^29^257^32
 ;;^UTILITY(U,$J,358.3,3132,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3132,1,1,0)
 ;;=1^205.00
 ;;^UTILITY(U,$J,358.3,3132,1,8,0)
 ;;=8^Myeloid Leukemia w/o Remission
 ;;^UTILITY(U,$J,358.3,3132,2)
 ;;=^267531
 ;;^UTILITY(U,$J,358.3,3133,0)
 ;;=205.01^^29^257^31
 ;;^UTILITY(U,$J,358.3,3133,1,0)
 ;;=^358.31IA^8^2
 ;;^UTILITY(U,$J,358.3,3133,1,1,0)
 ;;=1^205.01
 ;;^UTILITY(U,$J,358.3,3133,1,8,0)
 ;;=8^Myeloid Leukemia in Remission
